Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Profit After Tax: 2009-2025

Historic Profit After Tax for Corcept Therapeutics (CORT) over the last 13 years, with Sep 2025 value amounting to $19.7 million.

  • Corcept Therapeutics' Profit After Tax fell 58.34% to $19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.1 million, marking a year-over-year decrease of 25.18%. This contributed to the annual value of $141.2 million for FY2024, which is 33.04% up from last year.
  • Per Corcept Therapeutics' latest filing, its Profit After Tax stood at $19.7 million for Q3 2025, which was down 44.04% from $35.1 million recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Profit After Tax registered a high of $47.2 million during Q3 2024, and its lowest value of $15.9 million during Q1 2023.
  • Over the past 3 years, Corcept Therapeutics' median Profit After Tax value was $30.7 million (recorded in 2024), while the average stood at $29.3 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first spiked by 88.87% in 2023, then plummeted by 58.34% in 2025.
  • Quarterly analysis of 5 years shows Corcept Therapeutics' Profit After Tax stood at $32.1 million in 2021, then plummeted by 48.21% to $16.6 million in 2022, then skyrocketed by 88.87% to $31.4 million in 2023, then declined by 1.94% to $30.7 million in 2024, then crashed by 58.34% to $19.7 million in 2025.
  • Its last three reported values are $19.7 million in Q3 2025, $35.1 million for Q2 2025, and $20.5 million during Q1 2025.